{
  "abstract": "The incorporation of immune checkpoint inhibitors (ICIs) has transformed the management of advanced non-small cell lung cancer, establishing immunotherapy as a cornerstone of treatment. However, the therapeutic benefit remains heterogeneous, and identifying factors that influence response is essential to advancing precision oncology. Among these factors, sex is a biologically plausible yet incompletely understood determinant.",
  "authors": [
    {
      "affiliations": [
        "IDOR, Salvador, Brazil",
        "Grupo Brasileiro de Oncologia Torácica, Porto Alegre, Brazil"
      ],
      "name": "Eldsamira Mascarenhas"
    },
    {
      "affiliations": [
        "Grupo Brasileiro de Oncologia Torácica, Porto Alegre, Brazil",
        "Thoracic Oncology Reference Center, A.C.Camargo Cancer Center, São Paulo, Brazil"
      ],
      "name": "Vladmir Cláudio Cordeiro de Lima"
    }
  ],
  "title": "Sex differences in immunotherapy for lung cancer: balance or bias?",
  "uid": "6852c1c5-0d9c-5c10-b27e-331a93eaf670"
}